Literature DB >> 2621579

Enantioselective aspects of the disposition of dl-threo-methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder.

J W Hubbard1, N R Srinivas, D Quinn, K K Midha.   

Abstract

It has been shown previously that immediate-release dl-threo-methylphenidate (Ritalin) undergoes stereoselective disposition in human adults as well as in children with attention deficit-hyperactivity disorder. Although the sustained-release formulation of dl-threo-methylphenidate (Ritalin-SR) has been demonstrated to be effective in sustaining the attention of the children with attention deficit-hyperactivity disorder, there are no data on plasma levels of methylphenidate after administration of the sustained-release formulation. The purpose of this present investigation was twofold: (1) to determine whether the levels of methylphenidate were sustained for over a time period of 8 h, and (2) to examine enantioselective aspects of the pharmacokinetics following the ingestion of the sustained-release formulation. Six children with attention deficit-hyperactivity disorder were given 20 mg of sustained-release dl-threo methylphenidate. Plasma samples were harvested for a period up to 12 h following ingestion of the drug. The levels of both the enantiomers were sustained for a period of 8 h (the plasma levels of d-methylphenidate were 8- to 10-fold higher than those of the l-enantiomer in the profiles of all six children). Mean areas under the plasma level time curves were 132.78 +/- 92.47 ng.h/mL for d-methylphenidate and 12.73 +/- 7.37 ng.h/mL for l-methylphenidate. The values of oral clearance and apparent volume of distribution calculated for l-enantiomer were higher than the corresponding values for the d-antipode.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2621579     DOI: 10.1002/jps.2600781113

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

Review 1.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 2.  Pharmacokinetics and clinical effectiveness of methylphenidate.

Authors:  H C Kimko; J T Cross; D R Abernethy
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.

Authors:  David J Heal; David M Pierce
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Quantitative Characterization of the Smoothness of Extended-release Methylphenidate Pharmacokinetic Profiles.

Authors:  Michelle D Po; Roberto Gomeni; Bev Incledon
Journal:  Innov Clin Neurosci       Date:  2022 Jul-Sep

5.  Enantioselective analysis of ritalinic acids in biological samples by using a protein-based chiral stationary phase.

Authors:  Jianhua Zhang; Yulin Deng; Jim Fang; Gordon McKay
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

6.  Nonlinear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers.

Authors:  T Aoyama; H Kotaki; T Sasaki; Y Sawada; Y Honda; T Iga
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.

Authors:  N R Srinivas; J W Hubbard; E D Korchinski; K K Midha
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

Review 8.  Risks and benefits of drugs used in the management of the hyperactive child.

Authors:  A M Fox; M J Rieder
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 9.  Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate.

Authors:  Mark L Wolraich; Melissa A Doffing
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.

Authors:  Feng Liu; Haruka Minami; Raul R Silva
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.